Related Experiment Video
Updated: Mar 30, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.3K
Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem
Aidan Hollis1, Paul Grootendorst2
1Professor, Department of Economics, University of Calgary, Calgary, AB.
Healthcare Policy = Politiques De Sante
|November 17, 2015
Summary
Alberta introduced a new generic drug pricing policy where more manufacturers mean lower prices. This study explores the reasons behind this inverse relationship in drug pricing across Canadian provinces.
Area of Science:
- Health Policy
- Pharmaceutical Economics
- Canadian Healthcare System
Background:
- Generic drug pricing is a significant factor in healthcare costs.
- Regulatory bodies are exploring innovative pricing strategies to manage expenses.
- The introduction of a new pricing model in Alberta marks a shift in Canadian pharmaceutical policy.
Purpose of the Study:
- To analyze the rationale behind Alberta's new generic drug pricing policy.
- To understand the inverse relationship between manufacturer numbers and drug prices.
- To evaluate the potential impact of this policy on the Canadian pharmaceutical market.
Main Methods:
- Policy analysis of the new pricing model.
- Economic review of drug pricing mechanisms.
- Comparative study of provincial pharmaceutical regulations.
Main Results:
- The new policy establishes an inverse correlation between the number of generic drug manufacturers and drug prices.
- This model aims to incentivize competition and reduce overall drug expenditures.
- Early indications suggest a potential for significant cost savings.
Conclusions:
- Alberta's pricing policy represents a novel approach to controlling generic drug costs.
- The model's success may influence pharmaceutical pricing strategies in other Canadian provinces.
- Further research is needed to assess the long-term economic and clinical outcomes.
More Related Videos
Related Concept Videos
01:17Drug Nomenclature
3.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.7K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
352
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
352
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
243
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
243
01:24Dosage Regimen: Individualization
280
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
280
01:02Prescription, Nonprescription and Orphan Drugs
1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K